This is one hot tech discussion! Protein therapeutics have great potential, but significant limitations to their utility. Dr. Dan Mandell of GRO Biosciences explains how they are using a non-standard library of amino acids to increase protein presentation. Along with glycosylation and other modifications, the proteins are more therapeutically active, as such changes can improve issues like stability and visibility to the immune system. The technologies are being used to design therapeutic solutions for autoimmune diseases, such as myasthenia gravis. This is a technology dense episode that stretches the bounds of molecular biology.
Fler avsnitt av Talking Biotech with Dr. Kevin Folta
Visa alla avsnitt av Talking Biotech with Dr. Kevin FoltaTalking Biotech with Dr. Kevin Folta med Kevin Folta finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
